Precision Medicine Policy and Treatment (PreEMPT) Model
- National Human Genome Research Institute
- National Institute of Child Health and Human Development
Project Summary
The Precision Medicine Policy and Treatment (PreEMPT) Model has been exploring the clinical impact, cost, and cost-effectiveness of newborn genomic sequencing to prevent illness or facilitate early detection. In the current round of the PreEMPT Model, we have been extending our microsimulation model to examine the lifetime impact of newborn genomic sequencing for a wider array of diseases. We are also considering the impact of targeted screening of siblings of children identified with pathogenic variants, as well as the clinical and economic consequences of race-conscious genomic sequencing. Our projections will provide valuable guidance to ongoing discussions surrounding the adoption of newborn genomic sequencing.
Aims
Specific aims of this project are:
- Estimate benefits, risks, and cost-effectiveness of newborn genomic sequencing, accounting for the full life course of risks and spanning multiple cohorts
- Evaluate strategies for implementing cascade testing
- Evaluate strategies for newborn genomic sequencing while accounting for race and ethnicity